Andere Sprachen Avacta Group Plc

Aktien

A2ADP0

GB00BYYW9G87

AVCT

Biotechnologie

Markt geschlossen - London S.E. Andere Börsenplätze 17:35:21 12.06.2026			% 5 Tage	Veränd. 1. Jan.
71,00 ^GBX	+3,65 %		-0,70 %	+22,41 %

05.06.	Avacta Group nimmt 9 Millionen GBP für Anleiherückzahlungen auf	AN
05.06.	Avacta Therapeutics nimmt 9 Millionen GBP durch Aktienemission ein	MT

Andere Sprachen

05.06.	Avacta Group raises GBP9 million for bond repayments
05.06.	Avacta Therapeutics Raises GBP9 Million from Share Issue
01.06.	Avacta Therapeutics Presents Updated Clinical Data for Ava6000 in Salivary Gland Cancers At Asco 2026
01.06.	Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
01.06.	Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
29.05.	EARNINGS AND TRADING: Blencowe updates Orom-Cross net present value
29.05.	Avacta : Annual Report and Accounts for the year ending 31 December 2025
29.05.	Avacta Group plc Announces Board Changes
29.05.	Avacta Therapeutics Names Chairman Designate
19.05.	Avacta Group annual loss widens as cancer treatment trial results loom
19.05.	Avacta Therapeutics reports group revenues of £6.31 million for year ended December 31, 2025
19.05.	Avacta Group continues to explores multiple commercial opportunities with strategic partners
19.05.	Unaudited Preliminary Results for the Year Ended December 31, 2025
19.05.	Avacta Group Plc Reports Earnings Results for the Full Year Ended December 31, 2025
06.05.	Avacta : presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
06.05.	Avacta presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
06.05.	Avacta Therapeutics Presents New Comparisons Of Pre\|CISION Payload Release Versus Approved ADCs And AVA6207 Dual Payload Delivery
21.04.	Vaalco says remainder of 2026 to be "very profitable"
21.04.	Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre\|CISION® delivery platform
21.04.	Avacta Therapeutics Presents Favorable Data for AVA6103 and Showcases Dual Payload pre\|CISION Platform At AACR 2026
14.04.	Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders
09.04.	Somero Enterprises extends buyback to USD6.0 million
09.04.	Avacta hails "important milestones" in start of "transformative" year
08.04.	Avacta : Announces 2026 Science Day Event
31.03.	Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre\|CISION® exatecan peptide drug conjugate